MARKET

ZVRA

ZVRA

Zevra Therapeutics Inc
NASDAQ
9.87
-0.11
-1.10%
After Hours: 9.89 +0.02 +0.20% 19:59 03/16 EDT
OPEN
10.54
PREV CLOSE
9.98
HIGH
10.71
LOW
9.85
VOLUME
2.02M
TURNOVER
--
52 WEEK HIGH
13.16
52 WEEK LOW
6.19
MARKET CAP
579.48M
P/E (TTM)
7.28
1D
5D
1M
3M
1Y
5Y
1D
Zevra Pharmaceuticals: SDX Monetization, Debt Elimination, and Miplyffa Ramp Support Buy Rating
TipRanks · 5h ago
3 Best Stocks to Buy Today, 3/16/2026, According to Top Analysts
TipRanks · 12h ago
Zevra Shares Jump After Selling SDX Portfolio For $50M
Benzinga · 14h ago
This Qualcomm Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Benzinga · 14h ago
Zevra Sells SDX Portfolio and Resolves Litigation
TipRanks · 15h ago
Zevra Therapeutics Agrees To Sell Its Serdexmethylphenidate Portfolio, Including AZSTARYS And KP1077, To Commave Therapeutics For $50M
Benzinga · 16h ago
This Cohu Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga · 16h ago
Zevra Therapeutics sells SDX portfolio to Commave for $50M
TipRanks · 16h ago
More
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Webull offers Zevra Therapeutics Inc stock information, including NASDAQ: ZVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZVRA stock methods without spending real money on the virtual paper trading platform.